MRC1 and breast neoplasm: The reported low percentage of dMMR breast-cancer cases may be attributed to the lack of companion diagnostics assays (CDx) and/or specific guidelines for MMR analysis in breast tumors, as well as the utilization of different testing methods, such as the direct sequencing of microsatellite markers, NGS, and IHC for the four MMR proteins.